Nathan Caffo is listed as an executive officer on 1 SEC Form D filing by 1 issuer in Mar 2013: Presage Biosciences, Inc. (Seattle, WA — other health care — 2013; $8M reported sold to 51 investors).
What this means One deal on file with the SEC, filed Mar 2013. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
The issuer belongs to the sponsor group Presage (2 issuers, $16.1M reported sold, 2010–2024).
What this means A sponsor group is one team that sets up a new company for each deal. Presage has 2 companies on file and $16.1M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 1 public filing for Nathan Caffo and found 1 difference: No amendment in the last 12 months on an offering that may still be open.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.